Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
The inhibitor STM2457 can reduce the m6A level in cancer cells by inhibiting the IGFBP3/AKT signaling axis, thus exerting anticancer effects in vitro and in vivo (127)
Additionally, GHK-Cu has demonstrated antimetastatic properties in research settings, adding to its range of observed biological effects
Label the vial immediately with the reconstitution date and final concentration
mesenchymal phenotypes) and using metabolic profiling for personalized treatment selection
Nevertheless, the clinical application of NA is limited because the pharmacological dosing of it induces cutaneous flushing via activation of a G protein-coupled receptor, GPR109A
US$ 27.12
US$ 20.58
US$ 20.22
US$ 22.87
US$ 28.25
